TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01422928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medical Acupuncture
Description: Subjects will be asked to report symptom concerns. Subjects are requested to wear loose clothing as most acupoints lie at or distal to the elbow and knee.~Sterile single use steel needles (ITO Adiquip 0.25 x 4.0 cm) will be inserted to a depth of 1 - 2 cm at acupoints thought to impact positively on the immune system. An ITO ES-160 Electrostimulator will be used to mimic the pecking technique of manual stimulation. Following needle insertion by the acupuncturist, a nurse or acupuncture student may assist by attaching electrodes to provide electrical stimulation. A 0.3 ms duration, 4 HZ, alternating current will be delivered with voltage set just below the pain threshold of the patient. After 20 minutes, the needles will be removed. Acupoints will include:~* GV.14~* LI.11 (bilateral)~* SP.6 (bilateral)~* SP.10 (bilateral)~* ST.36 (bilateral)~Additional points may be added based on the symptom concerns reported.
Study: NCT00503113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 3mg intravenous (iv) injection every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 3mg intravenous (iv) infusion every 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70mg per oral (po) weekly
Study: NCT03507686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB111
Description: Administered as specified in the treatment arm.
Study: NCT04402918

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: biological samples day of delivery
Description: mother samples: serology, viremia, nasopharyngeal swab, vaginal swab, placenta swab, piece of placenta newborn: serology, viremia, nasopharyngeal aspiration
Study: NCT01237821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BenzaClin
Description: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effaclar
Description: Topical, Bid, 12 weeks
Study: NCT00502593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine (GSK1562902A)
Description: 2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine (GSK1562902A)
Description: 2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine (GSK1562902A)
Description: 2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: 2 doses, intramuscular injection on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: 2 doses, intramuscular injection on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: 2 doses, intramuscular injection on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: 2 doses, intramuscular injection on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: 2 doses, intramuscular injection on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: 2 doses, intramuscular injection on Days 0 and 21.
Study: NCT04035512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: The procedure for the writing group will be as follow:~on day 1 the researcher will call the participant at designed time and will provide a brief introduction to the writing task. Participant will be asked to go in a quiet place in their house where they would have no interruptions but can still be close to the phone. Next, participants were given standardized instructions. Then participants will ask to start writing immediately after hanging up the phone and to write for 20 minutes. The researcher will call the participants after 20 minutes. The procedure for the second and third writing days will be identical.~The above method was previously tested by Zakowski et al., 2004.
Study: NCT00493623

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.v. single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 3mg i.v. single dose
Study: NCT03299270

Intervention type: OTHER
Intervention: Questionnaires
Description: Quality of Life and Functional recovery questionnaires
Study: NCT04292769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 10mg / d, intravenous administration d-5 ～ d-1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-CIK
Description: Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;
Study: NCT02288598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal TDCS
Description: 20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluency Training
Description: Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Fluency Training
Description: Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
Study: NCT01612104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological First Aid
Description: A cognitive behavioral (CBT) method structuring and focusing psychological therapy sessions with children and adolescents having been exposed to potential trauma
Study: NCT04027829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Intravenous infusion of dexmedetomidine at the rate of 0.5mcg/kg for 10 min, then 0.5mcg/kg/hr for 50 min.
Study: NCT03824184

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manipulation of endometrium
Description: Manipulation of endometrium with saline

Intervention type: PROCEDURE
Group type: OTHER
Intervention: manipulation of endometrium
Description: Manipulation of endometrium with saline
Study: NCT00589901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine and cyclophosphamide
Description: capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14
Study: NCT00286507

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.
Description: Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.
Description: Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling
Study: NCT04622306

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B
Description: Condom functionality study to determine failure rates

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B
Description: Condom functionality study to determine failure rates

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B
Description: Condom functionality study to determine failure rates
Study: NCT02817074

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MIND Diet
Description: 3-year dietary counseling to adhere to the MIND diet and for mild weight loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mild Weight Loss
Description: 3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mild Weight Loss
Description: 3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss
Study: NCT02499276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV, NAVA, PAV, Variable-PSV
Description: Each patient enrolled in the study will be ventilated in all the following modes: PSV, NAVA, PAV and variable PSV
Study: NCT02041767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: One single injection of 1g of ertapenem before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: One single injection of 1g of ertapenem before surgery
Study: NCT03897023

Intervention type: BIOLOGICAL
Intervention: Gut Microbiota
Description: Status of microbiota
Study: NCT01572350

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grid laser
Description: Grid laser therapy acts as the standard to refer to as it is the treatment which is currently accepted by EMDDNT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Triamcinolone 4 mg followed by modified grid laser therapy after 3-4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (1.25 mg initially, weeks 6 and 12) followed by modified grid laser therapy after3-4 weeks
Study: NCT01252381

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 12 weeks Strength exercise training
Description: Training 3 times a week, leg extensions and leg press

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 weeks Strength exercise training
Description: Training 3 times a week, leg extensions and leg press
Study: NCT02248831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recording Doppler ultrasound signals noninvasively
Description: Using ultrasound noninvasively and recording Doppler signals from the right chest wall
Study: NCT03572244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-Lok
Description: A microgrooved abutment will be placed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Machined
Description: A machined transmucosal healing abutment will be placed
Study: NCT02520830

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry Group
Description: 22 grams freeze-dried blueberry powder per day. Sustained intake (2x 11 grams daily over 1 month) of a drink consisting on freeze-dried wild blueberry powder dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Sustained intake (2x 11 grams daily over 1 month) of a drink consisting in placebo powder dissolved in water
Study: NCT01422460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma (Preparation Rich in Growth Factors)~intra articular injection 2ml~Arms: Platelet Rich Plasma (Preparation Rich in Growth Factors)
Study: NCT01061216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal insulin delivery: BD Research Catheter Set
Description: 1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set
Description: 1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)
Study: NCT03352973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active tDCS on the dlPFC
Description: During active tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the active tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tDCS on the dlPFC
Description: During the sham tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the sham tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
Study: NCT02758132

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg enzalutamide by mouth daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg enzalutamide by mouth daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: 1000 mg abiraterone by mouth daily
Study: NCT01367912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol tablet
Description: received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol tablet
Description: received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
Study: NCT04087746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intra-vitreal injection of AVEGF AFLIBERCEPT in group I

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intra-vitreal injection of AVEGF Ranibizumab in group 2
Study: NCT03762330

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COPD structured self-management plan.
Description: Education plan , including knowledge of the disease, healthy life habits, correct use of inhalers, skills to control symptoms and strategies to face the disease and exacerbations
Study: NCT03601507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT01765413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella-zoster virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03505060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA CON-S env
Description: Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IHV01
Description: Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%; administered by intramuscular injection in the deltoid.
Study: NCT02758132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg prednisone by mouth twice daily
Study: NCT02285647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant - Oral
Description: Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant - IV
Description: IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
Study: NCT04172623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-Time Smoking Intervention
Description: Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Adult smokers will receive standard outpatient tobacco treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Adult smokers will receive standard outpatient tobacco treatment.
Study: NCT04066647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg
Description: 1 mg IV dexamethasone will be pushed and miRNA levels will be checked at baseline just before injection and then at 15, 30, 45, and 60 minutes after injection.
Study: NCT04001933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPOP Intervention
Description: The intervention consists of two 15-minute interactive modules (maternal and infant OH), integrated into 2 group prenatal care sessions. Led by trained prenatal care providers (facilitators), the maternal module includes discussion of common OH problems during pregnancy, importance of OH, importance and safety of OH care during pregnancy, hands-on skills-building activities of learning and practicing proper tooth brushing and self-assessment of gum health, and presentation of illustrated flossing and OH promotion guides. The infant module includes discussion of infant oral hygiene, avoiding saliva sharing, proper nutrition, and importance of a dental visit by the first birthday. Activities in both modules utilize separate tool kits including tooth brushes, fluoride toothpaste, and other supplies.
Study: NCT04962620

Intervention type: DRUG
Intervention: Bovhyaluronidase azoximer
Description: Rectally or vaginally 1 suppository of Longidaze every 2 days. The main course of treatment - 10 suppositories (for 30 days). Then (according to the doctor's decision) supportive therapy is prescribed for 1 suppository 1 time in 7 days. Course of supportive treatment - 17 suppositories for another 120 days. The patients took dienogest according to the instructions for use.
Study: NCT02007616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-action video game training
Description: Based on cognitive training Lumosity
Study: NCT02167425

Intervention type: OTHER
Intervention: IMAT
Description: The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.

Intervention type: OTHER
Intervention: IMAT
Description: The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
Study: NCT00357357

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HF0220
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HF0220
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HF0220
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HF0220
Description: comparison of different dosages of drug
Study: NCT02846545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to golimumab.
Study: NCT02231632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Poliomyelitis vaccine (Human Diploid Cell)
Description: 6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell)
Description: 6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
Study: NCT03055182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation program
Description: Patients participate during 4 weeks to a physical rehabilitation program.